• Creative Medical Technology Holdings filed a new U.S. provisional patent application to expand IP protection for its Ultrasome cell-free regenerative platform.
• Application targets product composition, potency testing, manufacturing controls, stability, delivery methods, broadening development beyond the initial knee osteoarthritis program.
• Ultrasome pilot knee osteoarthritis study reported about 93% of participants had clinically meaningful mobility and pain improvements, with no serious adverse events.
• Platform is derived from the Olastrocel regenerative program, using a GMP master cell bank supported by an FDA Drug Master File.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Creative Medical Technology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609170900PRIMZONEFULLFEED9828535) on September 17, 2026, and is solely responsible for the information contained therein.